677 related articles for article (PubMed ID: 3120587)
1. Effect of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E.
Knopp RH; Walden CE; Warnick GR; Albers JJ; Ginsberg J; McGinnis BM
Am J Med; 1987 Nov; 83(5B):75-84. PubMed ID: 3120587
[TBL] [Abstract][Full Text] [Related]
2. Fenofibrate affects the compositions of lipoproteins.
Goldberg AC; Schonfeld G; Anderson C; Dillingham MA
Am J Med; 1987 Nov; 83(5B):60-5. PubMed ID: 3318455
[TBL] [Abstract][Full Text] [Related]
3. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia.
Knopp RH; Brown WV; Dujovne CA; Farquhar JW; Feldman EB; Goldberg AC; Grundy SM; Lasser NL; Mellies MJ; Palmer RH
Am J Med; 1987 Nov; 83(5B):50-9. PubMed ID: 3318454
[TBL] [Abstract][Full Text] [Related]
4. Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolaemia.
Stohler R; Keller U; Riesen WF
Eur J Clin Pharmacol; 1989; 37(2):199-203. PubMed ID: 2507323
[TBL] [Abstract][Full Text] [Related]
5. Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia.
Mellies MJ; Stein EA; Khoury P; Lamkin G; Glueck CJ
Atherosclerosis; 1987 Jan; 63(1):57-64. PubMed ID: 3548734
[TBL] [Abstract][Full Text] [Related]
6. Changes in plasma lipid and apolipoprotein levels between heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments.
Lane DM; Alaupovic P; Knight-Gibson C; Dudley VS; Laughlin LO
Am J Cardiol; 1995 Jun; 75(16):1124-9. PubMed ID: 7762498
[TBL] [Abstract][Full Text] [Related]
7. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
[TBL] [Abstract][Full Text] [Related]
8. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
[TBL] [Abstract][Full Text] [Related]
9. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
[TBL] [Abstract][Full Text] [Related]
10. Effects of alpha- and beta-adrenergic antagonists on plasma apolipoproteins and forearm blood flow in patients with mild hypertension.
Sacks FM; Creager MA; Gallagher SJ; Loscalzo J; Dzau VJ
Am J Med; 1989 Jan; 86(1B):8-13. PubMed ID: 2563311
[TBL] [Abstract][Full Text] [Related]
11. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
Vega GL; Ma PT; Cater NB; Filipchuk N; Meguro S; Garcia-Garcia AB; Grundy SM
Am J Cardiol; 2003 Apr; 91(8):956-60. PubMed ID: 12686335
[TBL] [Abstract][Full Text] [Related]
12. Plasma and lipoprotein lipids and apolipoproteins AI, AII and B in patients with chronic airflow limitation.
Bolton CH; Mulloy E; Harvey J; Downs LG; Hartog M
J R Soc Med; 1989 Feb; 82(2):91-2. PubMed ID: 2494326
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition.
Bard JM; Dallongeville J; Hagen E; Pfister P; Ose L; Fruchart JC; Duriez P
Metabolism; 1995 Nov; 44(11):1447-54. PubMed ID: 7476333
[TBL] [Abstract][Full Text] [Related]
14. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
16. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
Schaefer EJ; Lamon-Fava S; Cole T; Sprecher DL; Cilla DD; Balagtas CC; Rowan JP; Black DM
Atherosclerosis; 1996 Nov; 127(1):113-22. PubMed ID: 9006811
[TBL] [Abstract][Full Text] [Related]
17. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC
Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein particle analysis comparing simvastatin and fenofibrate.
Bard JM; Parra HJ; Luc G; Camare R; Ziegler O; Dachet C; Bruckert E; Douste-Blazy P; Drouin P; Jacotot B
Atherosclerosis; 1991 Dec; 91 Suppl():S29-34. PubMed ID: 1789814
[TBL] [Abstract][Full Text] [Related]
19. Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia.
Weisweiler P; Merk W; Jacob B; Schwandt P
Eur J Clin Pharmacol; 1986; 30(2):191-4. PubMed ID: 3709644
[TBL] [Abstract][Full Text] [Related]
20. Lipid and apoprotein modifications in body builders during and after self-administration of anabolic steroids.
Baldo-Enzi G; Giada F; Zuliani G; Baroni L; Vitale E; Enzi G; Magnanini P; Fellin R
Metabolism; 1990 Feb; 39(2):203-8. PubMed ID: 2105436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
